Blog
RSS FeedPosted by Michael Wonder on 14 Nov 2024
Qalsody: HAS update
8 November 2024 - On 10 October, the High Authority for Health (HAS) issued a negative decision on the request for ...
Posted by Michael Wonder on 03 Jul 2024
HAS clarifies the framework of the “bet” on early access to medicines
24 June 2024 - Committed to a process of continuous development of its methods, the High Authority of Health is launching ...
Posted by Michael Wonder on 17 Aug 2023
Do France, Germany, and Italy agree on the added therapeutic value of medicines?
17 August 2023 - The Health Technology Assessment of medicines is performed separately at the country level with some differences, but ...
Posted by Michael Wonder on 10 Aug 2023
Patient and citizen participation at the organisational level in health technology assessment: an exploratory study in five jurisdictions
8 August 2023 - While patient participation in individual health technology assessments has been frequently described in the literature, patient and ...
Posted by Michael Wonder on 01 Dec 2022
Reimbursed access to Bylvay (odevixibat) approved in France for patients with PFIC 1 & 2
30 November 2022 - Albireo Pharma today announced that the Committee Economic Health Products has approved reimbursed access to Bylvay (odevixibat) ...
Posted by Michael Wonder on 06 Sep 2022
COVID-19: a global opinion on bivalent vaccines in mid-September
5 September 2022 - The EMA has just modified the marketing authorisations granted to messenger RNA vaccines developed by Moderna and ...
Posted by Michael Wonder on 26 Apr 2022
HAS decides in favour of reimbursement of Paxlovid
25 April 2022 - After authorising early access to Paxlovid for the treatment of COVID-19 on January 22, HAS assessed ...
Posted by Michael Wonder on 21 Apr 2022
Hansa Biopharma granted added benefit ASMR 3 by French Transparency Commission for Idefirix (imlifidase) as desensitisation treatment for highly sensitised kidney transplant patients
20 April 2022 - The opinion by the Transparency Commission follows after Idefirix was granted a funded Early Access Program by ...
Posted by Michael Wonder on 13 Apr 2022
Europe’s new HTA system spurs more debate, concern
12 April 2022 - Fresh round of discussions around health technology assessment. ...
Posted by Michael Wonder on 24 Mar 2021
The contribution of French patient and consumer groups to health technology assessments over a 2 year period: an observational retrospective study
22 March 2021 - In 2017, The French National Authority for Health created an open, online, systematic contribution process to enable ...
Posted by Michael Wonder on 17 Sep 2020
Transparency Commission publishes its opinion on Veklury
17 September 2020 - Gilead withdrew its request for the reimbursement of remdesivir in France on 31 August 2020. ...
Posted by Michael Wonder on 22 Apr 2020
Managed Entry Agreements: policy analysis from the European perspective
21 April 2020 - This article begins with a short review of the existing taxonomy of managed entry agreements and includes ...
Posted by Michael Wonder on 03 Dec 2019
Could or should we use MCDA in the French HTA process?
3 December 2019 - Over the last decade, an increasing literature has been highlighting the benefits of introducing multi-criteria decision analysis ...
Posted by Michael Wonder on 16 Dec 2018
Transparency Commission publishes its opinion for Kymriah
14 December 2018 - Opinion published following an examination of written submissions on 12 December 2018. ...
Posted by Michael Wonder on 09 Dec 2018
Transparency Commission publishes its opinion for Yescarta
7 December 2018 - Opinion published following an examination of written submissions on 5 December 2018. ...